Eyeing Novartis deal, Akcea trumpets lipoprotein drug data

Ionis affiliate Akcea Pharma has new data for its antisense drug for elevated lipoprotein levels in patients with cardiovascular disease that it hopes will entice Novartis into a licensing deal.